NRA-CANDESARTAN TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
03-05-2022
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
CANDESARTAN CILEXETIL
から入手可能:
NORA PHARMA INC
ATCコード:
C09CA06
INN（国際名）:
CANDESARTAN
投薬量:
4MG
医薬品形態:
TABLET
構図:
CANDESARTAN CILEXETIL 4MG
投与経路:
ORAL
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription
製品概要:
Active ingredient group (AIG) number: 0135220001; AHFS:
認証ステータス:
APPROVED
承認日:
2022-05-03
製品の特徴
______________________________________________________________________________
_NRA-Candesartan Product Monograph_
_ Page 1 of 39_
PRODUCT MONOGRAPH
PR
NRA-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Nora Pharma Inc.
1565 Lionel-Boulet Blvd.
Varennes, Quebec
J3X 1P7
Submission Control Numbers: 256986
DATE OF PREPARATION:
May 3, 2022
______________________________________________________________________________
_NRA-Candesartan Product Monograph_
_ Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................3
SUMMARY PRODUCT
INFORMATION...........................................................................3
INDICATIONS AND CLINICAL
USE.................................................................................3
CONTRAINDICATIONS......................................................................................................4
WARNINGS AND PRECAUTIONS
....................................................................................5
ADVERSE
REACTIONS.......................................................................................................9
DRUG
INTERACTIONS.....................................................................................................15
DOSAGE AND ADMINISTRATION
................................................................................19
OVERDOSAGE...................................................................................................................22
ACTION AND CLINICAL
PHARMACOLOGY...............................................................22
STORAGE AND
STABILITY.............................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................25
PART II: SCIENTIFIC
INFORMATION.....................................................................................26
PHARMACEUTICAL
INFORMATION....................
完全なドキュメントを読む
